HC Wainwright Reaffirms Buy Rating for Pliant Therapeutics (NASDAQ:PLRX)
HC Wainwright reaffirmed their buy rating on shares of Pliant Therapeutics (NASDAQ:PLRX – Free Report) in a research report released on Friday, Benzinga reports. HC Wainwright currently has a $38.00 price objective on the stock. Other equities analysts also recently issued reports about the stock. Oppenheimer reduced their price objective on shares of Pliant Therapeutics […]
More Stories
Tokio Marine Asset Management Co. Ltd. Acquires 492 Shares of CME Group Inc. (NASDAQ:CME)
Tokio Marine Asset Management Co. Ltd. increased its holdings in shares of CME Group Inc. (NASDAQ:CME – Free Report) by...
Tokio Marine Asset Management Co. Ltd. Has $1.48 Million Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
Tokio Marine Asset Management Co. Ltd. raised its holdings in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 0.8% during...
Arch Capital Group Ltd. (NASDAQ:ACGL) Shares Acquired by Metis Global Partners LLC
Metis Global Partners LLC raised its position in shares of Arch Capital Group Ltd. (NASDAQ:ACGL – Free Report) by 26.6%...
Metis Global Partners LLC Grows Position in First Solar, Inc. (NASDAQ:FSLR)
Metis Global Partners LLC boosted its position in First Solar, Inc. (NASDAQ:FSLR – Free Report) by 9.3% during the third...
Huntington National Bank Sells 111 Shares of Dover Co. (NYSE:DOV)
Huntington National Bank reduced its position in shares of Dover Co. (NYSE:DOV – Free Report) by 0.5% in the third...
Cable Hill Partners LLC Sells 443 Shares of Fidelity National Financial, Inc. (NYSE:FNF)
Cable Hill Partners LLC reduced its stake in Fidelity National Financial, Inc. (NYSE:FNF – Free Report) by 10.7% during the...